03/02/2026
For hundreds of years, Indigenous Amazonian traditions have worked with the secretions of Phyllomedusa bicolor frog, Kambo, with deep respect and purpose. Today, modern science continues exploring the remarkable bioactive peptides found within this medicine, studying their potential applications in pain management and beyond.
It’s powerful to witness research increasingly validating what traditional knowledge has long held — that nature contains sophisticated compounds capable of influencing human biology in profound ways. When ancient wisdom and modern pharmacology meet, something meaningful happens.
I honor this medicine with reverence, responsibility, and humility. The conversation around peptides and pain science is evolving, and it reminds us that the natural world still holds discoveries that could reshape how we approach health and healing.
If you feel called to explore this work in a grounded, intentional way, reach out to learn more about upcoming sessions.
Infinite Blessings from Kambo Holistic Healing
Pharmacologists at the Federal University of São Paulo, studying the skin secretions of the giant monkey frog (Phyllomedusa bicolor) — used for centuries by Amazonian Matses hunters in traditional ritual practices — have isolated and characterized a neuropeptide called Dermorphin-B7 that blocks pain signaling through a novel receptor not previously identified in human pain biology. In clinical trials with chronic pain patients unresponsive to opioids, NSAIDs, and nerve blocks, a single subcutaneous injection of synthetic Dermorphin-B7 provided complete pain relief for an average of 47 days — with zero opioid receptor activity, zero addiction potential, and zero tolerance development. The jungle pharmacopoeia just produced pain medicine's most significant finding in decades. 🐸
Standard pain management operates almost entirely through opioid receptors (morphine, oxycodone), cyclooxygenase inhibition (ibuprofen, aspirin), or sodium channel blockade (lidocaine). All three pathways have fundamental limitations: opioids produce addiction and tolerance, COX inhibitors carry cardiovascular and GI risks with long-term use, and sodium channel blockers can't be delivered systemically without cardiac toxicity. Dermorphin-B7 acts on a newly characterized nociceptor receptor — GPR-34 variant — that modulates C-fiber pain transmission without touching any of these existing pathways. It's a fourth route into pain biology that pharmacology didn't know existed.
Chronic pain affects 50 million Americans and costs $635 billion annually in treatment and lost productivity. The opioid epidemic — which killed 80,000 Americans in 2023 — was partly a consequence of the absence of non-addictive alternatives for severe chronic pain. A peptide that provides month-long complete pain relief without addiction potential would be the most important development in pain pharmacology since the discovery of morphine itself.
UNIFESP has licensed Dermorphin-B7 synthesis to two US pharmaceutical companies for Phase II trials. The frog that Amazonian tribes have revered for their pain-relieving properties may have been holding the future of medicine all along.
Source: Federal University of São Paulo / UNIFESP, Nature Chemical Biology 2025
